Figure 2. TRIP13 enhances cellular protein deubiquitination.

(A–C) Representational and pathway analysis of approximately 1900 differentially expressed genes in B cells from Eμ-Myc/Trip13^TG versus Eμ-Myc/Trip13^WT mice (P < 0.001) displayed in volcano plot (A) and bar graphs of GO terms (B) and KEGG pathways (C). Ubiquitin-related (Ub-related) and proteasome-related terms or pathways are indicated by red arrows. (D) Western blot analysis of Ub, TRIP13, and β-actin in EV and TRIP13-OE ARP1 cells treated overnight with or without 10 nM BTZ. (E) Western blot analysis of Ub, TRIP13, and GAPDH in ARP1 cells transfected with a doxycycline-inducible (DOX-inducible) TRIP13 shRNA, treated with or without DOX for 72 hours, followed by treatment with or without 10 nM BTZ. (F) Western blot analysis of Ub, Trip13, and Gapdh in thymus (T) and spleen (S) from Trip13^TG and Trip13^WT mice.